Local Gentamicin Delivery From Resorbable Viscous Hydrogels Is Therapeutically Effective

Clinical Orthopaedics and Related Research

Volumn 473, Issue 1, 2015, Pages 337-347

  Overstreet, Derek ^a   McLaren, Alex ^b   Calara, Francis ^b   Vernon, Brent ^c   McLemore, Ryan ^b  

^a Sonoran Biosciences   (United States)

^b BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^c Arizona State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; CREATININE; GENTAMICIN; POLY(N ISOPROPYLACRYLAMIDE CO DIMETHYL GAMMA BUTYROLACTONE ACRYLATE CO JEFFAMINE ACRYMALIDE); UNCLASSIFIED DRUG; UREA; ANTIINFECTIVE AGENT; DRUG CARRIER; DRUG IMPLANT; HYDROGEL; POLYMER; TOPICAL ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG EFFICACY; FEMALE; HYDROGEL; KIRSCHNER WIRE; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; RABBIT; RAT; STAPHYLOCOCCUS AUREUS; SUSTAINED DRUG RELEASE; UREA NITROGEN BLOOD LEVEL; ANIMAL; BIODEGRADABLE IMPLANT; BLOOD; BONE WIRE; CHEMICALLY INDUCED; CHEMISTRY; DEBRIDEMENT; DISEASE MODEL; DRUG EFFECTS; DRUG IMPLANT; KIDNEY; KIDNEY DISEASE; MAXIMUM TOLERATED DOSE; MEDICINAL CHEMISTRY; METABOLISM; MICROBIOLOGY; PROSTHESIS-RELATED INFECTIONS; RADIUS; SOLUBILITY; SPRAGUE DAWLEY RAT; STAPHYLOCOCCAL INFECTIONS; SURGERY; TIME; TOXICITY; VISCOSITY;

ABSORBABLE IMPLANTS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; BLOOD UREA NITROGEN; BONE WIRES; CHEMISTRY, PHARMACEUTICAL; CREATININE; DEBRIDEMENT; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG IMPLANTS; FEMALE; GENTAMICINS; HYDROGELS; KIDNEY; KIDNEY DISEASES; MAXIMUM TOLERATED DOSE; POLYMERS; PROSTHESIS-RELATED INFECTIONS; RABBITS; RADIUS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; VISCOSITY;

EID: 84922080125     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-014-3935-9     Document Type: Article

References (65)

1. Adams K, Couch L, Cierny G, Calhoun J, Mader JT. In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop Relat Res. 1992;278:244–252.
2. Alt V, Bitschnau A, Böhner F, Heerich KE, Magesin E, Sewing A, Pavlidis T, Szalay G, Heiss C, Thormann U, Hartmann S, Pabst W, Wenisch S, Schnettler R. Effects of gentamicin and gentamicin-RGD coatings on bone ingrowth and biocompatibility of cementless joint prostheses: an experimental study in rabbits. Acta Biomater. 2011;7:1274–1280.
3. Alt V, Bitschnau A, Osterling J, Sewing A, Meyer C, Kraus R, Meissner SA, Wenisch S, Domann E, Schnettler R. The effects of combined gentamicin-hydroxyapatite coating for cementless joint prostheses on the reduction of infection rates in a rabbit infection prophylaxis model. Biomaterials. 2006;27:4627–4634.
4. Ambrose CG, Gogola GR, Clyburn TA, Raymond AK, Peng AS, Mikos AG. Antibiotic microspheres: preliminary testing for potential treatment of osteomyelitis. Clin Orthop Relat Res. 2003;415:279–285.
5. Anderson GG, O’Toole GA. Innate and induced resistance mechanisms of bacterial biofilms. Curr Top Microbiol Immunol. 2008;322:85–105.
6. Arciola CR, Campoccia D, Gamberini S, Donati ME, Pirini V, Visai L, Speziale P, Montanaro L. Antibiotic resistance in exopolysaccharide-forming Staphylococcus epidermidis clinical isolates from orthopaedic implant infections. Biomaterials. 2005;26:6530–6535.
7. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis. 1979;140:576–580.
8. Bertrand N, Fleischer JG, Wasan KM, Leroux J-C. Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes. Biomaterials. 2009;30:2598–2605.
9. Buranapanitkit B, Oungbho K, Ingviya N. The efficacy of hydroxyapatite composite impregnated with amphotericin B. Clin Orthop Relat Res. 2005;437:236–241.
10. Cabrita HB, Croci AT, de Camargo OP, de Lima ALLM. Prospective study of the treatment of infected hip arthroplasties with or without the use of an antibiotic-loaded cement spacer. Clin São Paulo Braz. 2007;62:99–108.
11. Campoccia D, Montanaro L, Arciola CR. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomaterials. 2006;27:2331–2339.
12. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771–1776.
13. Cierny G. Surgical treatment of osteomyelitis. Plast Reconstr Surg. 2011;127(Suppl 1):190S–204S.
14. Cierny G, Mader JT, Penninck JJ. The Classic: A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7–24.
15. Cohen L, Lapkin R, Kaloyanides GJ. Effect of gentamicin on renal function in the rat. J Pharmacol Exp Ther. 1975;193:264–273.
16. Cui Z, Lee BH, Vernon BL. New hydrolysis-dependent thermosensitive polymer for an injectable degradable system. Biomacromolecules. 2007;8:1280–1286.
17. Davies JP, O’Connor DO, Burke DW, Harris WH. Influence of antibiotic impregnation on the fatigue life of Simplex P and Palacos R acrylic bone cements, with and without centrifugation. J Biomed Mater Res. 1989;23:379–397.
18. de Beer D, Stoodley P, Lewandowski Z. Measurement of local diffusion coefficients in biofilms by microinjection and confocal microscopy. Biotechnol Bioeng. 1997;53:151–158.
19. DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, Mirick GR, Lamborn KR, O’Donnell RT, DeNardo GL. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res. 2003;9:3854S–3864S.
20. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193.
21. Elkhatib WF, Khairalla AS, Ashour HM. Evaluation of different microtiter plate-based methods for the quantitative assessment of Staphylococcus aureus biofilms. Future Microbiol. 2014;9:725–735.
22. FDA Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville, MD, USA: Office of Training and Communications, Division of Drug Information, HFD-240 Center for Drug Evaluation and Research, Food and Drug Administration; 2005.
23. Frame PT, Phair JP, Watanakunakorn C, Bannister TW. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis. 1977;135:952–956.
24. Frutos P, Torrado S, Perez-Lorenzo ME, Frutos G. A validated quantitative colorimetric assay for gentamicin. J Pharm Biomed Anal. 2000;21:1149–1159.
25. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13:34–40.
26. Giers MB, McLaren AC, Plasencia JD, Frakes D, McLemore R, Caplan MR. Spatiotemporal quantification of local drug delivery using MRI. Comput Math Methods Med. 2013;2013:149608.
27. Gilbert DN, Plamp C, Starr P, Bennett WM, Houghton DC, Porter G. Comparative nephrotoxicity of gentamicin and tobramycin in rats. Antimicrob Agents Chemother. 1978;13:34–40.
28. Gilbert P, Maira-Litran T, McBain AJ, Rickard AH, Whyte FW. The physiology and collective recalcitrance of microbial biofilm communities. Adv Microb Physiol. 2002;46:202–256.
29. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. Role of the accessory gene regulator (AGR) in pathogenesis of staphylococcal osteomyelitis. Infect Immun. 1995;63:3373–3380.
30. Ginebra MP, Traykova T, Planell JA. Calcium phosphate cements as bone drug delivery systems: a review. J Control Release. 2006;113:102–110.
31. Girard LP, Ceri H, Gibb AP, Olson M, Sepandj F. MIC versus MBEC to determine the antibiotic sensitivity of Staphylococcus aureus in peritoneal dialysis peritonitis. Perit Dial Int. 2010;30:652–656.
32. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–332.
33. Iarikov D, Demian H, Rubin D, Alexander J, Nambiar S. Choice and doses of antibacterial agents for cement spacers in treatment of prosthetic joint infections: review of published studies. Clin Infect Dis. 2012;55:1474–1480.
34. Koort JK, Suokas E, Veiranto M, Mäkinen TJ, Jalava J, Törmälä P, Aro HT. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. J Biomed Mater Res A. 2006;78:532–540.
35. Levine NS, Lindberg RB, Mason AD, Pruitt BA. The quantitative swab culture and smear: a quick, simple method for determining the number of viable aerobic bacteria on open wounds. J Trauma. 1976;16:89–94.
36. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol. 2008;322:107–131.
37. Loeb WF, Quimby F. Clinical Chemistry of Laboratory Animals. 2nd ed. Philadelphia, PA, USA: CRC Press; 1999.
38. Mah TF, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001;9:34–39.
39. Mayhall CG, Medoff G, Marr JJ. Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin. Antimicrob Agents Chemother. 1976;10:707–712.
40. McLaren A, Giers MB, Fraser J, Hosack L, Caplan MR, McLemore R. Antimicrobial distribution from local delivery depends on dose: a pilot study with MRI. Clin Orthop Relat Res. 2014 Feb 8 [Epub ahead of print].
41. Miller R, McLaren A, Leon C, McLemore R. Mixing method affects elution and strength of high-dose ALBC: a pilot study. Clin Orthop Relat Res. 2012;470:2677–2683.
42. Miller RB, McLaren AC, Leon CM, Vernon BL, McLemore R. Surfactant-stabilized emulsion increases gentamicin elution from bone cement. Clin Orthop Relat Res. 2011;469:2995–3001.
43. Mingeot-Leclercq M-P, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003–1012.
44. Moran JM, Greenwald AS, Matejczyk M-B. Effect of gentamicin on shear and interface strengths of bone cement. Clin Orthop Relat Res. 1979;141:96–101.
45. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42:1915–1922.
46. Nelson CL, Hickmon SG, Skinner RA. Treatment of experimental osteomyelitis by surgical débridement and the implantation of bioerodable, polyanhydride-gentamicin beads. J Orthop Res. 1997;15:249–255.
47. Nie L, Nicolau DP, Tessier PR, Kourea HP, Browner BD, Nightingale CH. Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. J Orthop Res. 1998;16:76–79.
48. Nishimura S, Tsurumoto T, Yonekura A, Adachi K, Shindo H. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases. J Orthop Sci. 2006;11:46–50.
49. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res. 2002;66:86–92.
50. Overstreet DJ, Huynh R, Jarbo K, McLemore RY, Vernon BL. In situ forming, resorbable graft copolymer hydrogels providing controlled drug release. J Biomed Mater Res A. 2013;101:1437–1446.
51. Overstreet DJ, McLemore RY, Doan BD, Farag A, Vernon BL. Temperature-responsive graft copolymer hydrogels for controlled swelling and drug delivery. Soft Mater. 2013;11:294–304.
52. Penner MJ, Duncan CP, Masri BA. The in vitro elution characteristics of antibiotic-loaded CMW and Palacos-R bone cements. J Arthroplasty. 1999;14:209–214.
53. Ramage G, Tunney MM, Patrick S, Gorman SP, Nixon JR. Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials. 2003;24:3221–3227.
54. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother. 2006;50:55–61.
55. Schierholz JM, Beuth J, König D, Nürnberger A, Pulverer G. Antimicrobial substances and effects on sessile bacteria. Zentralbl Bakteriol. 1999;289:165–177.
56. Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival. J Bone Joint Surg Br. 2001;83:403–407.
57. Skinner R, Hickmon S, Nelson C, Evans R. Correlation of histology with culture to more accurately determine experimental osteomyelitis. Orthop Trans. 1994:18598–99.
58. Smeltzer MS, Thomas JR, Hickmon SG, Skinner RA, Nelson CL, Griffith D, Parr TR Jr, Evans RP. Characterization of a rabbit model of staphylococcal osteomyelitis. J Orthop Res. 1997;15:414–421.
59. Sorensen TS, Sorensen AI, Merser S. Rapid release of gentamicin from collagen sponge. Acta Orthop Scand. 1990;61:353–356.
60. Swieringa AJ, Goosen JHM, Jansman FGA, Tulp NJA. In vivo pharmacokinetics of a gentamicin-loaded collagen sponge in acute periprosthetic infection: serum values in 19 patients. Acta Orthop. 2008;79:637–642.
61. Tang W, Zhao J, Sha B, Liu H. Adsorption and drug release based on β-cyclodextrin-grafted hydroxyapatite composite. J Appl Polym Sci. 2013;127:2803–2808.
62. VV Van de Belt H, Neut D, Schenk W, van Horn JR, van der Mei HC, Busscher HJ. Staphylococcus aureus biofilm formation on different gentamicin-loaded polymethylmethacrylate bone cements. Biomaterials. 2001;22:1607–1611.
63. Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother. 2003;47:317–323.
64. Walton K, Dorne JLCM, Renwick AG. Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans. Food Chem Toxicol. 2004;42:261–274.
65. Zaske DE, Cipolle RJ, Rotschafer JC, Solem LD, Mosier NR, Strate RG. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother. 1982;21:407–411.